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Abstract
Background: The aims of this analysis were to investigate treatment completion and adherence among people
with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided
therapy for chronic HCV genotypes 2/3 infection.
Methods: ACTIVATE was a multicenter clinical trial recruited between 2012 and 2014. Participants with genotypes
2/3 were treated with directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin for 12
(undetectable HCV RNA at week 4) or 24 weeks (detectable HCV RNA at week 4). Outcomes included treatment
completion, PEG-IFN adherence, ribavirin adherence, and sustained virological response (SVR, undetectable HCV
RNA >12 weeks post-treatment).
Results: Among 93 people treated, 59% had recently injected drugs (past month), 77% were receiving OST and
56% injected drugs during therapy. Overall, 76% completed treatment. Mean on-treatment adherence to PEG-IFN
and ribavirin were 98.2% and 94.6%. Overall, 6% of participants missed >1 dose of PEG-IFN and 31% took <95% of
their prescribed ribavirin., Higher treatment completion was observed among those receiving 12 vs. 24 weeks of
treatment (97% vs. 46%, P < 0.001) while the proportion of participants with 95% on-treatment ribavirin adherence
was similar between groups (67% vs. 72%, P = 0.664). Receiving 12 weeks of therapy was independently associated
with treatment completion. No factors were associated with 95% RBV adherence. Neither recent injecting drug use
at baseline nor during therapy was associated with treatment completion or adherence to ribavirin. In adjusted
analysis, treatment completion was associated with SVR (aOR 23.9, 95% CI 2.9–193.8).
Conclusions: This study demonstrated a high adherence to directly observed PEG-IFN and self-administered
ribavirin among people with ongoing injecting drug use or receiving OST. These data also suggest that shortening
therapy from 24 to 12 weeks can lead to improved treatment completion. Treatment completion was associated
with improved response to therapy.
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Background
Among people who inject drugs (PWID), there is a sub-
stantial burden of hepatitis C virus (HCV) infection [1, 2].
Adherence [3–6] and treatment completion [3] are associ-
ated with sustained virologic response (SVR). Adherence
to HCV therapy among PWID is of particular interest
given the high cost of new direct-acting antiviral (DAA)
therapies and the importance of maximizing the chance of
successful therapy.
Adherence refers to the extent to which a person’s be-
haviour, with respect to timing, dosage and frequency of
taking medication, corresponds with agreed recommenda-
tions from a healthcare provider [7, 8]. Medication adher-
ence research has been performed in a variety of medical
conditions, including diabetes, hypertension, arthritis, pul-
monary diseases, HIV and others [9] and on average, pa-
tients take 79% of prescribed doses of medications [7].
Adherence to HCV therapy is often defined measuring
“80/80 adherence”, or the receipt of ≥80% of scheduled
doses for ≥80% of the scheduled treatment period [7].
However, this definition combines the two distinct con-
cepts of treatment completion and missed doses during
therapy. Understanding the two concepts individually is
important for understanding adherence in this population
of PWID.
Among health practitioners, HCV therapy is some-
times withheld from people with ongoing injecting drug
use, based on concerns of poor adherence to therapy,
and risk of reinfection [10]. However, there are few stud-
ies that have evaluated adherence to HCV therapy
among people with ongoing injecting drug use. Under-
standing adherence to therapy among PWID is a key
component to the scale-up of DAA therapy among this
population.
ACTIVATE is a multicentre international trial evaluat-
ing the efficacy of response-guided directly observed
pegylated-interferon and self-administered ribavirin ther-
apy for chronic HCV genotypes 2/3 infection among
people with ongoing injecting drug use or receiving opioid
substitution therapy (OST). Participants with genotypes 2/
3 were treated with directly observed peg-interferon
alfa-2b and self-administered ribavirin for either
12 weeks (in those with undetectable HCV RNA at week 4,
RVR) or 24 weeks (in those with detectable HCV RNA at
week 4, no RVR). The primary analysis from this study
demonstrated that cirrhosis (vs. no/mild fibrosis [adjusted
odds ratio (aOR) 0.33, 95% CI 0.13, 0.86]) predicted re-
duced SVR, while response at week 4 was associated with
increased SVR (aOR 8.11, 95% CI 2.73, 24.10) [11]. While
the PEG-IFN based regimen used in this study has been re-
placed in many settings with new DAA therapies, data on
adherence to HCV therapy among PWID is still needed.
Given the increased tolerability and simplicity of new DAA
regimens compared to PEG-IFN based therapies, results in
this study likely represent a lower bound of adherence
among PWID using new DAA therapies.
The primary aim of this analysis was to evaluate treat-
ment completion, adherence to therapy and associated
factors (including impact of treatment duration) in the
ACTIVATE study. Further, this analysis also investigated
the effect of treatment completion and on-treatment ad-
herence on response to HCV therapy (as measured by
SVR).
Methods
Study participants
From May 11 2012, to September 30 2014, participants
were enrolled at 17 sites in Australia (n = 5), Belgium
(n = 2), Canada (n = 3), Germany (n = 1), Norway
(n = 2), Switzerland (n = 3) and the United Kingdom
(n = 1). The last participant visit was July 15 2015. Study
recruitment was conducted through a network of drug
and alcohol clinics (n = 3), office-based practices (n = 2),
hospital clinics (n = 9), and community clinics (n = 3).
Participants had to be more than 18 years of age, have
chronic HCV genotype 2 or 3 infection, be HCV
treatment-naïve, and have reported recent injecting drug
use, defined as injecting drug use within 12 weeks of enrol-
ment. Due to slower than anticipated recruitment, on June
26 2013, a study protocol amendment was implemented to
also include people currently receiving OST with no recent
injection drug use and people who had injected within
24 weeks prior to enrolment. Participants with HIV infec-
tion and decompensated liver disease were excluded. Full
eligibility has been previously published [11].
Study design and intervention
ACTIVATE was an international, multicentre open-
label study. Participants received directly observed
pegylated interferon alfa-2b (PEG-IFN, 1.5 μg/kg/week)
and self-administered ribavirin (RBV, 800–1400 mg
daily, weight-based).
Participants with a rapid virological response [RVR,
defined as non-quantifiable HCV RNA (<15 IU/ml de-
tected and <15 IU/ml undetected) or undetectable HCV
RNA on qualitative assay at week 4] received 12 weeks
of therapy (shortened duration). Participants without an
RVR [defined as quantifiable HCV RNA (≥15 IU/ml) or
detectable HCV RNA on qualitative assay at week 4] re-
ceived 24 weeks of therapy (standard duration).
Study assessments
Screening assessments included serum HCV RNA levels,
HCV genotype, standard laboratory and clinical testing
and self-reported behavioural questionnaires (details
have been previously reported [11]).
HCV RNA levels and HCV genotype and subtype were
measured as previously described [11]. HCV RNA testing
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was performed on samples collected at screening, baseline,
and weeks 4, 12, 24, 36 and 48 (standard duration). All ad-
verse events were recorded and graded according to a
standard scale (details have been previously reported [11]).
Directly observed PEG-IFN adherence was recorded
by the study nurse. RBV adherence was determined
through the return of unused RBV pills. Self-reported
RBV adherence was also measured monthly during study
visits while on treatment by a patient-administered ques-
tionnaire and was used where returned pill counts were
unavailable for that time point.
All participants completed a self-administered question-
naire at enrolment (pre-treatment assessment), at baseline
(treatment commencement), every 4th week during treat-
ment, and at 12 and 24 weeks of follow-up. The
questionnaires collected information on demographics
(age, gender, ethnicity, education level, housing status and
history of imprisonment), drug and alcohol use, injecting
risk behaviours (injection frequency, use of non-sterile
needles, needle and syringe borrowing or lending, and
injecting paraphernalia [spoons or mixing containers, drug
solution/mix, water or filter] sharing), drug treatment, and
symptoms of psychological distress (Depression Anxiety
Stress Scale, DASS-21). Stable housing was defined as liv-
ing in a rented or privately owned house or flat..
Social functioning was measured using the short-form
Opioid Treatment Index Social Functioning Scale [12].
Social functioning are scored as a sum of the coded re-
sponses with higher scores indicating lower social func-
tioning. Alcohol consumption was evaluated by the
Table 1 Baseline demographic and clinical characteristics stratified by 12 week and 24 week duration (n = 93)
Characteristic, n (%) Overall (n = 93) 12 week (n = 61) 24 week (n = 26)
Age, median (25%, 75%) 41 (35–49) 41 (34–49) 40 (35–48)
Male sex, n (%) 77 (83) 49 (80) 23 (88)
Drug use in the last 6 months
(injecting/non-injecting)
77 (83) 48 (79) 25 (96)
Injecting drug use in the last month 55 (59) 39 (64) 15 (58)
Heroin 33 (35) 23 (37) 10 (38)
Cocaine 10 (11) 7 (11) 3 (12)
Amphetamines 14 (15) 7 (11) 6 (23)
Other opiates 11 (12) 8 (13) 3 (12)
Benzodiazapines 2 (2) 2 (3) 0 (0)
Injecting drug use frequency in the last month
Never 38 (41) 22 (36) 11 (42)
< daily 40 (43) 29 (48) 10 (38)
> daily 15 (16) 10 (16) 5 (19)
Opioid substitution treatment (ever) 82 (88) 56 (92) 21 (81)
OST and recent injecting (past month) at enrolment
No OST, recent injecting 30 (32) 20 (33) 9 (33)
OST, no recent injecting 23 (25) 15 (25) 5 (19)
OST, recent injecting 40 (43) 26 (43) 12 (44)
OST and recent injecting (past month) at baseline
No OST, recent injecting 21 (23) 14 (23) 6 (23)
OST, no recent injecting 34 (37) 21 (34) 8 (31)
OST, recent injecting 38 (41) 26 (43) 12 (46)
Stage of liver disease
No or mild fibrosis (F0-F1) 63 (68) 44 (72) 16 (62)
Moderate or advanced fibrosis (F2-F3) 20 (22) 12 (20) 5 (19)
Cirrhosis (F4) 10 (11) 5 (8) 5 (19)
Study site distribution
Europe 38 (41) 24 (39) 13 (50)
Australia 40 (43) 27 (44) 9 (35)
Canada 15 (16) 10 (16) 4 (15)
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Alcohol Use Disorders Identification Test-Consumption
(AUDIT-C), derived from the first three questions of the
full AUDIT (scores ≥3 and ≥4 indicate hazardous con-
sumption or active alcohol use disorders among women
and men, respectively) [13]. Depression was measured
using DASS 21 with a depression score of ≥10 indicating
depression.
Study definitions
Treatment completion
Participants with no early discontinuation of PEG-IFN/
RBV therapy prior to the per-protocol planned end of
treatment (12 or 24 weeks for shortened or standard ther-
apy respectively) were defined as having completed treat-
ment. Participants were deemed to have discontinued
treatment early if for any reason (e.g. physician advised
treatment discontinuation, virological non-response, lost
to follow up, patient decision, etc.) a participant did not
reach the per protocol defined end of treatment.
On-treatment adherence
On-treatment adherence was calculated by determining
the number of doses taken as proportion of the expected
number of doses during the time on treatment. This
measures the proportion of doses received from the time
that treatment was initiated until treatment was discon-
tinued or completed.
Dose modification
A physician directed increase or reduction in the dose at
any time during treatment.
Study outcomes
The main study outcomes were to assess treatment com-
pletion, and on-treatment PEG-IFN and RBV adherence.
Evaluation of adherence was based on all participants
who received at least one injection of PEG-IFN. Treat-
ment success was defined as undetectable qualitative
HCV RNA rates at week 12 (SVR).
Statistical analysis
Treatment completion and 95% on-treatment adherence
(at least 95% of scheduled doses were taken) were
assessed. Bi-variate comparisons of characteristics of
participants and different measures of adherence across
treatment arms were tested using the chi-squared test or
Fisher’s exact test as appropriate. Time to treatment dis-
continuation was evaluated using Kaplan Meier analysis.
The impact of treatment completion and on-treatment
adherence (both PEG-IFN and ribavirin) on SVR were
also evaluated.
Logistic regression analyses were used to estimate crude
and adjusted odds ratios (OR) and corresponding 95%
confidence intervals (95% CI) to identify predictors of
HCV treatment completion and on-treatment ribavirin
adherence (at least 95% of scheduled doses were taken). In
unadjusted analyses, potential predictors were determined
a priori and included sex, age, education, accommodation,
employment, current OST treatment, social functioning,
current depression, alcohol consumption, injection drug
use at baseline (past month), injecting behaviours
(frequency and drug injected), and treatment arm. Social
functioning was calculated using a validated scale from
Fig. 1 Weekly PEG-IFN adherence among HCV genotype 2/3 partici-
pants on shortened (12 weeks; n = 61; panel a) and standard therapy
(24 weeks; n = 26; panel b). Each row represents a study participant.
Dark green boxes represent a full prescribed dose was received, light
green boxes represent an adjusted dose was received, and white
boxes represent a missed dose
Cunningham et al. BMC Infectious Diseases  (2017) 17:420 Page 4 of 12
the Opiate Treatment Index [27] that addresses employ-
ment, residential stability, and inter-personal conflict as
well as social support. A higher score reflects poorer social
functioning. This scale has been validated among opiate
users in Australia (range, 0–48) [27]. All variables with
p < 0.20 in the bivariate analysis were considered for
multivariate logistic regression models using a backward
stepwise approach, sequentially eliminated and subject to
the result of a likelihood ratio test. Statistically significant
differences were assessed at p < 0.05; p values are two-
sided. Adjusted models for factors associated with SVR
were adjusted for all variables found to be associated with
SVR in the primary analysis (fibrosis stage and treatment
group) as well as by study site using cluster-robust stand-
ard errors [11].
Finally, to determine whether later study visits were
associated with RBV adherence, generalized estimating
equation (GEE) methods were used. Unadjusted and
adjusted GEE models were specified using a gaussian
family function. Odds ratios (ORs) with corresponding
95% confidence intervals (CIs) and p-values were
calculated. All analyses were performed using the
Table 2 Adherence to PEG-IFN and RBV among the overall population, those on 12 weeks of therapy, and those on 24 weeks of
therapy
Variable Overall (n = 93) 12 week (n = 61) 24 week (n = 26)
Treatment completion 71 (76) 59 (97) 12 (46)
Mean on-treatment PEG-IFN adherence percent, (SD) 98.2 (4.5) 98.5 (3.1) 98.7 (3.0)
Mean on-treatment ribavirin adherence percent, (SD) 94.6 (8.8) 94.8 (8.1) 94.1 (10.8)
Missed doses of PEG-IFN, n (%)
No missed doses 87 (94) 59 (97) 22 (85)
1 missed dose 6 (6) 2 (3) 4 (15)
2–5 missed doses 0 (0) 0 (0) 0 (0)
> 5 missed doses 0 (0) 0 (0) 0 (0)
Missed doses of ribavirin, n (%)
100% of doses taken 22 (25) 16 (26) 5 (20)
95%- < 100% of doses taken 38 (44) 25 (41) 13 (52)
90%- < 95% of doses taken 15 (17) 11 (18) 4 (16)
80%- < 90% of doses taken 7 (8) 6 (10) 1 (4)
< 80% of doses taken 5 (6) 3 (5) 2 (8)
Number of weeks of PEG-IFN therapy, n (%)
24 weeks 12 (13) NA 12 (46)
13 to 23 weeks 3 (3) NA 3 (3)
7 to 12 weeks 69 (74) 61 (100) 8 (31)
0 to 6 weeks 9 (10) 0 (0) 3 (12)
Weeks on PEG-IFN therapy
Mean, n (SD) NA 11.9 (0.65) 16.8 (7.8)
Median, n (IQR) NA 12 (12–12) 21 (10–24)
PEG-IFN dose-modification 9 (10) 3 (5) 6 (23)
Ribavirin dose-modification 21 (23) 12 (20) 9 (35)
Fig. 2 Time to treatment discontinuation among study participants
who were in the shortened (12 week; n = 61) and standard
(24 week; n = 26) arm
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statistical package Stata v13.1 (College Station, TX,
United States).
Results
Participant characteristics
A full description of the participant characteristics is de-
scribed in the primary paper [11]. In summary, 93 pa-
tients were enrolled in the study between May 2012 and
August 2014 and initiated PEG-IFN/ribavirin therapy:
median age 41, 83% male, 77% on OST, 59% injecting in
the past month (Table 1).
PEG-IFN and RBV adherence and early treatment
discontinuation
Of the 93 participants who initiated therapy, six partici-
pants discontinued therapy before week 4. Reasons for
discontinuing therapy prior to week 4 include side ef-
fects (n = 3), unwillingness to continue treatment
(n = 1), loss to follow up (n = 1), and imprisonment
(n = 1). Among the remaining 87 participants, 70%
(n = 61) were HCV RNA undetectable at week 4 (rapid
virological response, RVR) and were scheduled to receive
12 weeks of therapy (shortened duration) and 30%
(n = 26) did not have an RVR at week 4 and were sched-
uled to receive 24 weeks of therapy (standard duration).
An abbreviated description of participant adherence is
described in the primary paper [11]. Weekly PEG-IFN
adherence among those receiving 12 weeks of therapy
and 24 weeks of therapy is shown in Fig. 1. Among the
entire study population, 76% (n = 71) completed HCV
therapy (Table 2). Time to discontinuation stratified by
duration of therapy is shown in Fig. 2. The median time
to discontinuation was 12 weeks and 23 weeks in the
12 week and 24 week groups respectively. Mean on-
treatment adherence to PEG-IFN and ribavirin were 98%
and 95% (Table 2). Overall, 6% of participants missed >1
dose of PEG-IFN and 31% missed >5% of their doses of
ribavirin.
Completion of treatment was more frequent in the
12 week group compared to the 24 week group (97% vs.
46%, P < 0.001). In the 12 week group, completion of 0–
4, 5–8, and 9–12 weeks of therapy was demonstrated by
0% (n = 0), 2% (n = 1), and 98% (n = 60), respectively. In
the 24 week arm, completion of 0–4, 5–8, 9–12, 13–23,
and 24 weeks was demonstrated by 0% (n = 0), 19%
(n = 5), 23% (n = 6), 3% (n = 3) and 46% (n = 12) re-
spectively. Reasons for discontinuing prior to the
planned end of therapy include side effects (overall,
n = 11; 12 week, n = 1; 24 week, n = 7), patient unwill-
ingness (overall, n = 5; 12 week, n = 1; 24 week, n = 3),
patient lost to follow-up (overall, n = 4; 12 week, n = 0;
24 week, n = 3), and virological failure (overall, n = 1;
12 week, n = 0; 24 week, n = 1). The mean number of
weeks of PEG-IFN therapy was 11.9 and 16.8 weeks in
the 12 week and 24 week groups respectively.
The mean on-treatment PEG-IFN adherence was simi-
lar between those receiving 12 and 24 weeks of therapy
(98.5% vs. 98.7%, P = 0.811). The proportion of partici-
pants missing at least one dose of PEG-IFN while on
therapy was 3% in those receiving 12 weeks of therapy
Fig. 3 Four-weekly RBV adherence among HCV genotype 2/3
participants on shortened (12 weeks; n = 61; panel a) and standard
therapy (24 weeks; n = 26; panel b). Each row represents a study
participant. Colours represent each participant’s RBV adherence
during each four-week period with dark green representing 100%
adherence and red representing 0% adherence. White represents
discontinuation before completion of the corresponding time-point
while black represents missing data for both retuned pill counts and
patient reported adherence before treatment discontinuation
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Table 3 Unadjusted potential predictors of treatment completion among the study population (n = 93)
Number completed
treatment (%; n = 71
Number not completing
treatment (%; n = 22)
Unadjusted OR 95% CI P
Age (years)
≤ 41 38 (83) 8 (17) 1.00 - -
> 41 33 (70) 14 (30) 0.50 0.19–1.33 0.164
Gender
Female 13 (81) 3 (19) 1.00 - -
Male 58 (75) 19 (25) 0.70 0.18–2.74 0.613
Educationa
< Tertiary 52 (79) 14 (21) 1.00 - -
Tertiary or greater 18 (75) 6 (25) 0.81 0.27–2.42 0.703
Social functioning score
< 17 31 (78) 9 (23) 1.00 - -
≥ 17 40 (75) 13 (25) 0.89 0.34–2.36 0.820
Stable housing
No 17 (77) 5 (23) 1.00 - -
Yes 54 (76) 17 (24) 0.93 0.30–2.91 0.907
Current depressionb
No 30 (75) 10 (25) 1.00 - -
Yes 37 (80) 9 (20) 1.37 0.49–3.80 0.545
Hazardous alcohol
consumptionc
No 58 (81) 14 (19) 1.00 - -
Yes 11 (83) 2 (15) 1.71 0.35–8.43 0.512
Current OST
No 19 (70) 8 (30) 1.00 - -
Yes 52 (79) 14 (21) 1.56 0.57–4.32 0.388
Injecting (last month)
No 26 (68) 12 (32) 1.00 - -
Yes 45 (82) 10 (18) 2.08 0.79–5.47 0.139
Frequency of injecting
(last month)
Never 26 (68) 12 (32) 1.00 - -
Less than weekly 17 (77) 5 (23) 1.57 0.47–5.26 0.465
Weekly or greater 28 (85) 5 (15) 2.58 0.80–8.34 0.112
Heroin injecting
(last month)
No 43 (72) 17 (28) 1.00 - -
Yes 28 (85) 5 (15) 2.21 0.73–6.68 0.159
Cocaine injecting
(last month)
No 63 (76) 20 (24) 1.00 - -
Yes 8 (80) 2 (20) 1.27 0.25–6.48 0.774
Amphetamine injecting
(last month)
No 63 (80) 16 (20) 1.00 - -
Yes 8 (57) 6 (43) 0.34 0.10–1.12 0.075
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compared to 15% in those receiving 24 weeks of therapy
(P = 0.072).
Four-weekly RBV adherence among those receiving
12 weeks of therapy and 24 weeks of therapy is shown in
Fig. 3. Returned pill counts were used in 276 of the 284
on treatment visits in Fig. 3 (97%). In the case of missing
pill counts (n = 8) participant completed questionnaire
data was used where available (n = 7). Data was not
available, either from pill counts or patient completed
questionnaires for one study visit. The mean overall on-
treatment RBV adherence was similar between those re-
ceiving 12 and 24 weeks of therapy (94.8% vs. 94.1%,
P = 0.751). The mean on-treatment adherence to RBV
in the 12 week arm during weeks 1–4, 5–8, and 9–12
was 96.9%, 93.8% and 93.5% respectively. The mean on-
treatment adherence to RBV in the 24 week arm during
weeks 1–4, 5–8, and 9–12 was 96.6%, 88.3% and 95.2%
respectively. Overall 65% of participants had >95% on-
treatment RBV adherence.
Factors associated with treatment completion and on-
treatment RBV adherence
In unadjusted analyses, treatment completion occurred
more frequently in those with recent injecting at base-
line, recent heroin injecting at baseline, injecting weekly
or more in the past month, and those in the 12 week
arm but less often in people with recent amphetamine
injecting at baseline and those who were >41 years of
age (Table 3). The only factor that remained independ-
ently associated with treatment completion was short-
ened treatment arm (aOR 31.2, P = <0.001).
In unadjusted analyses, no factors were associated with
>95% on-treatment RBV adherence (Table 4). In GEE
analyses, later study visit was not associated with adher-
ence to RBV (OR 1.00, P = 0.489).
Impact of missed doses of PEG-IFN and RBV, and treat-
ment completion on SVR
In unadjusted analyses, SVR occurred more frequently
among those who completed treatment (OR 34.4,
P = <0.001). Neither 100% PEG-IFN adherence, nor >95%
RBV adherence were associated with SVR in unadjusted
analyses and were therefore not included in the adjusted
model. In adjusted analyses, when adjusted for all factors
found to be associated with SVR in the primary analysis
[11], treatment completion remained as being associated
with SVR (aOR 23.86, P = 0.003; Table 5).
Discussion
This study investigated treatment completion and the
adherence to response-guided directly observed PEG-
IFN and self-administered ribavirin treatment for
chronic HCV genotypes 2/3 among PWID with ongoing
drug use and those receiving OST. The results demon-
strated high adherence to directly observed PEG-IFN
and self-administered RBV therapy, particularly among
participants receiving 12 weeks, as opposed to 24 weeks,
of therapy. Being scheduled to receive 12 weeks of ther-
apy was an independent predictor of treatment comple-
tion. There were no independent predictors of >95%
RBV adherence in the population. Neither recent injec-
tion drug use prior to treatment, nor injection drug use
while on treatment, were associated with treatment
completion or >95% on-treatment RBV adherence. Fur-
ther, the majority of the sub-optimal treatment exposure
was due to early discontinuation of therapy rather than
missed doses while on therapy. Finally, while neither
PEG-IFN nor RBV adherence was an independent pre-
dictor of SVR, treatment completion was found to be an
independent predictor of SVR. These data have important
clinical implications informing HCV management among
PWID with ongoing drug use and those receiving OST in
the DAA era, given that the majority of licensed regimens
require only 12 weeks of therapy.
Overall, adherence to PEG-IFN/RBV therapy was high
with few participants (6%) missing ≥1 dose of PEG-IFN
while on therapy, with no one missing more than one
dose for a high on-treatment adherence of 98%. This is
consistent with previous studies of PEG-IFN adherence
where on-treatment adherence ranged from 74% to 99%
[3, 14–17]. While slightly lower than PEG-IFN adher-
ence, a similarly high on-treatment RBV adherence was
observed (94.6%) with 71% of participants taking at least
95% of their RBV doses. The proportion of the
Table 3 Unadjusted potential predictors of treatment completion among the study population (n = 93) (Continued)
Injecting on therapy
No 30 (83) 6 (17) 1.00 - -
Yes 41 (79) 11 (21) 0.75 0.25–2.24 0.601
Therapy duration*
24 weeks 13 (50) 13 (50) 1.00 - -
12 weeks 58 (95) 3 (5) 19.33 4.81–77.78 <0.001
*Among participants who attended study week 4
aMissing data for three participants
bMissing data for seven participants
cMissing data for eight participants; percentages refer to row percentages
Cunningham et al. BMC Infectious Diseases  (2017) 17:420 Page 8 of 12
Table 4 Unadjusted potential predictors of RBV adherence among the study population with available RBV adherence data (n = 86)
RBV adherence of 95% (%; n = 59) RBV adherence of < 95% (%; n = 27) Unadjusted OR 95% CI P
Age (years)
≤ 41 29 (66) 15 (34) 1.00 - -
> 41 30 (71) 12 (29) 1.25 0.50–3.11 0.632
Gender
Female 49 (69) 22 (31) 1.00 - -
Male 10 (67) 5 (33) 1.14 0.35–3.72 0.833
Educationa
< Tertiary 43 (69) 19 (31) 1.00 - -
Tertiary or greater 15 (71) 6 (29) 1.18 0.40–3.48 0.766
Social functioning score
< 17 29 (76) 9 (24) 1.00 - -
≥ 17 30 (63) 18 (38) 0.53 0.21–1.38 0.195
Current depressionb
No 24 (65) 13 (35) 1.00 - -
Yes 30 (68) 14 (32) 1.11 0.44–2.80 0.818
Hazardous alcohol consumptionc
No 48 (68) 23 (32) 1.00 - -
Yes 8 (67) 4 (33) 0.94 0.26–3.44 0.924
Current OST
No 16 (64) 9 (36) 1.00 - -
Yes 43 (70) 18 (30) 1.26 0.48–3.36 0.638
Injecting (last month)
No 22 (69) 10 (31) 1.00 - -
Yes 37 (69) 17 (31) 0.95 0.37–2.42 0.908
Frequency of injecting (last month)
Never 22 (69) 10 (31) 1.00 - -
Less than weekly 14 (67) 7 (33) 0.87 0.27–2.81 0.815
Weekly or greater 23 (70) 10 (30) 1.00 0.35–2.86 1.000
Heroin injecting (last month)
No 35 (66) 18 (34) 1.00 - -
Yes 24 (73) 9 (27) 1.33 0.51–3.46 0.554
Cocaine injecting (last month)
No 52 (68) 24 (32) 1.00 - -
Yes 7 (70) 3 (30) 0.77 0.25–4.44 0.940
Amphetamine injecting (last month)
No 51 (69) 23 (31) 1.00 - -
Yes 8 (67) 4 (33) 0.88 0.24–3.24 0.853
Injecting on therapy
No 25 (74) 9 (26) 1.00 - -
Yes 34 (65) 18 (35) 0.65 0.25–1.69 0.380
Therapy duration
24 weeks 18 (72) 7 (28) 1.00 - -
12 weeks 41 (67) 20 (33) 0.80 0.29–2.22 0.664
aMissing data for three participants
bMissing data for five participants
cMissing data for three participants; percentages refer to row percentages
Cunningham et al. BMC Infectious Diseases  (2017) 17:420 Page 9 of 12
population with >95% adherence is lower than was re-
ported in the C-EDGE CO-STAR trial (96%), a random-
ized controlled trial of elbasvir-grazoprevir in people
receiving stable opioid agonist therapy [18]. This is po-
tentially due to the higher toxicity of PEG-IFN/RBV
therapy or the increased pill burden due to the inclusion
of RBV. Also, the C-EDGE CO-STAR trial likely repre-
sents a more stable population given the inclusion of
only those on stable OST and the exclusion of those ac-
tively using drugs of potential abuse. As such, it is diffi-
cult to directly compare these results.
Participants who were allocated 12 weeks of therapy
demonstrated a higher proportion completing therapy
than those allocated 24 weeks of therapy. Recent injec-
tion drug use prior to and during treatment was not as-
sociated with PEG-IFN adherence, RBV adherence, or
treatment completion, consistent with previous data [3,
10, 19–22].
While PEG-IFN based therapies have recently been re-
placed by new DAA therapies in many settings, data on
the adherence to HCV therapies among PWID is still
needed. In many countries, concerns still exist regarding
the adherence to therapy among active PWID [10, 23]. As
a result many countries have restricted the use of DAA
therapies to those without current injecting [23–25]. A
better understanding of adherence among active injectors
is therefore needed to inform policy and remove the re-
strictions placed on DAA therapies. This data also high-
lights the positive effect of shortened therapy on
treatment completion in this population as pushes to fur-
ther shorten HCV therapy continue. This study includes
data on adherence to self-administered ribavirin, providing
some insight into adherence of an oral twice-daily antiviral
therapy. Given the increased tolerability and simplicity
DAA regimens compared to PEG-IFN and ribavirin-based
therapies, adherence should be comparable, if not better,
than that observed with twice-daily ribavirin, Further data
is needed to assess adherence to DAA-based therapy
among people with ongoing injecting drug use.
There are some limitations to this study. Adherence to
RBV was determined based on returned pill counts
where available and patient surveys where pill counts
were unavailable. While pill counts are generally a better
estimate of the true adherence as compared to patient
reported adherence [26], there is still the potential for
overestimation through lost pills. The measurement of
adherence to PEG-IFN was more robust, given that this
was a directly observed dose in the presence of the study
nurse who recorded when the dose was taken. Further,
adherence is a very complex phenomenon and may be
influenced by a number of unmeasured factors (e.g. past
experience with adherence to other medications,
patient-doctor relationships). Lastly, the small sample
size of this study is a limitation. With a larger sample
size, it would be possible to more accurately estimate
the true effects of various factors on HCV treatment ad-
herence and the true effect of treatment adherence on
SVR. In addition, while the international nature of this
study increases the generalizability to globally diverse
PWID populations, the participants recruited into this
study may represent a somewhat selected group, based
on improved engagement in care. Irrespective of these
limitations, this is the first international study to evalu-
ate adherence to HCV therapy among PWID and those
receiving OST.
Conclusions
This study demonstrates high adherence to response-
guided directly observed pegylated-interferon and self-
administered ribavirin therapy for chronic HCV geno-
types 2/3 infection among people with ongoing injecting
drug use or receiving OST. These data suggest that
shortening HCV therapy has the potential to increase
treatment completion among PWID. This is of particular
importance given the interest in evaluating shorter dura-
tions of DAA therapy. Further, injecting drug use both
prior to and during treatment was not associated with
reduced adherence to therapy or treatment completions.
Table 5 Unadjusted and adjusted models of adherence-related predictors of SVR among the study population
SVR (%) Unadjusted OR 95% CI P Adjusted OR 95% CI P
95% ribavirin adherence*
No 17 (63) 1.00 - - - - -
Yes 44 (73) 1.62 0.61–4.26 0.330 - - -
100% PEG-IFN adherence*
No 58 (67) 1.00 - - - - -
Yes 3 (50) 2.00 0.38–10.53 0.413 - - -
Completed therapy
No 2 (9) 1.00 - - 1.00 - -
Yes 59 (83) 34.41 6.90–171.55 0.000 23.86 2.94–193.84 0.003
The adjusted model is adjusted for all factors associated with SVR from the primary analysis [11]
*On-treatment adherence
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These data suggest that adherence to HCV therapy
among HCV infected PWID is not compromised by on-
going injection drug use and supports guidelines which
suggest that active PWID should not be excluded from
therapy; rather decisions should be made on a case-by-
case basis [27–30]. Further studies are needed to
characterize adherence to interferon-free DAA therapies
among PWID and those receiving OST to better under-
stand whether adherence is actually a problem in this
population in the DAA era.
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